Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: March 8, 2004
Last updated: June 3, 2013
Last verified: June 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)